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Abstract	
Septic	shock	remains	a	global	health	challenge	with	millions	of	cases	every	year,	high	rates	of	
mortality	and	morbidity,	impaired	quality	of	life	among	survivors	and	relatives,	and	high	resource	
use	both	in	developed	and	developing	nations.	Care	and	outcomes	are	improving	through	
organisational	initiatives	and	updated	clinical	practice	guidelines	based	on	clinical	research	mainly	
done	by	large	collaborative	networks.	This	progress	is	likely	to	continue	through	the	collaborative	
work	of	the	established	and	merging	trials	groups	in	many	parts	of	the	world	and	through	refined	
trial	methodology	and	translational	work.	In	this	review,	international	experts	summarize	the	
current	position	of	clinical	research	in	septic	shock	and	propose	a	research	agenda	to	advance	this	
field.	
	 	
Introduction	
Sepsis	has	been	extensively	researched	over	the	last	50	years.	We	can	better	define	the	host	
immune	response	to	infection	and	have	made	considerable	progress	in	the	provision	of	vital	organ	
support.	Today,	many	individuals	with	septic	shock,	who	would	previously	have	died,	will	survive	a	
reflection	of	improved	treatment	of	precipitating	infections,	better	and	safer	organ	support,	less	
iatrogenic	harm,	and	more	co-ordinated	and	effective	intensive	care	medicine.	However,	we	still	
lack	specific	therapies	to	directly	treat	the	dysregulated	host	response.	All	trials	of	interventions	
designed	to	manipulate	the	host’s	immune	response	during	sepsis	have	disappointed.	The	only	
therapy	with	initial	encouraging	results,	activated	protein	C	(APC)	[1],	was	subsequently	
withdrawn	due	to	neutral	results	in	the	confirmatory	trial	[2].		
Important	lessons	can	be	learned	from	recent	advances	in	the	understanding	and	treatment	of	
cancer.	Targeted	therapy	is	the	result	of	a	century	of	research	in	histological	and	anatomical	
classifications,	understanding	of	global	mechanisms	of	oncogenesis	and	anti-cancer	immunity	and,	
ultimately,	the	demonstration	of	highly	specific	immunological	signatures.	This	has	enabled	the	
design	of	specific	drugs	and	successful	clinical	trials.	This	process,	only	completed	in	a	few	cancer	
types	and	leading	to	approval	of	some	very	expensive	new	drugs,	may	serve	as	an	example	for	
sepsis	research.	
For	more	than	30	years,	multiple	editorials	and	reviews	have	emphasised	that	sepsis	is	a	
heterogeneous	syndrome,	depending	on	the	infectious	process	(e.g.,	microorganism,	focus	and	
speed	of	evolution)	and	on	the	specific	innate	and	adaptive	immune	response	of	an	individual	
patient	(Fig.	1).	In	hindsight,	it	was	naive	to	believe	that	one	drug	would	suit	all	cases,	act	on	all	
the	components	of	this	complex	phenomenon,	and	improve	outcome	for	all	patients.		
It	is	now	time	to	go	back	to	the	drawing	board	[3].	The	classification	of	patients	is	still	non-specific,	
even	using	the	new	definitions	[4].	We	thus	need	to	better	characterize	the	different	types	of	
sepsis	by	defining	more	homogeneous	groups	of	patients,	perhaps	based	on	their	biological	profile	
rather	than	clinical	criteria	alone.	Large	epidemiological	studies	and	classification	analyses	may	
help	to	identify	classes	of	clinical	phenotypes	and	genotypes	that	respond	differently	to	therapies.	
We	also	need	to	develop	and	validate	stratification	tools	that	rapidly	identify	patients	who	will	
respond	to	a	given	intervention.		
In	this	narrative	review,	invited	by	the	editorial	board	of	Intensive	Care	Medicine,	we	summarize	
the	current	position	of	the	field	of	clinical	research	in	sepsis	and	septic	shock	and	propose	a	
research	agenda	to	advance	this	field.	
What	is	the	current	standard	of	care	for	delivering	the	best	possible	sepsis	care?	
Arguably	the	most	accepted	international	standard	of	care	for	the	treatment	of	septic	shock	is	the	
set	of	guidelines	articulated	by	the	Surviving	Sepsis	Campaign	(SSC),	the	2016	iteration	of	which	
has	recently	been	published	[5].	These	guidelines	emphasise	the	use	of	screening	tools	to	allow	
early	recognition	of	sepsis	with	prompt	initiation	of	broad	spectrum	antimicrobial	therapy	guided	
by	pharmacokinetic/pharmacodynamic	principles,	microbiological	techniques	aiming	to	identify	
the	causative	agents,	and	appropriate	source	control.	All	institutions	should	have	strategies	to	
promote	awareness	of	sepsis-associated	hypotension	and	severe	hyperlactatemia	as	these	are	life-
threatening	conditions.	Identification	should	be	followed	by	appropriate	fluid	resuscitation	using	
an	empiric	dose	of	30	ml/kg	of	crystalloids	over	the	first	3	hours,	while	avoiding	starches.	Further	
fluid	resuscitation	should	be	guided	by	frequent	reassessment	of	hemodynamic	status	using	
appropriate	monitoring	and	evaluation	of	fluid	responsiveness.	Vasopressors	should,	in	general,	
be	initially	titrated	to	a	mean	arterial	pressure	of	65	mmHg,	with	norepinephrine	as	the	first-line	
therapy,	and	epinephrine	and	vasopressin	as	second-line	agents.	It	is	suggested	that	patients	with	
severe	hyperlactatemia	receive	hemodynamic	optimization	until	lactate	is	normalised.	Quality	of	
care	indicators	include	a	second	lactate	sampling	when	the	baseline	is	high,	and	re-assessment	of	
fluid	status	and	perfusion	(www.survivingsepsis.org/Bundles/Pages/default.aspx).		
	
Although	these	guidelines	are	based	on	the	best	available	evidence	as	assessed	by	a	group	of	
experts,	they	are	only	rarely	supported	by	high	quality	evidence.	Of	the	93	statements	in	the	2016	
iteration,	only	7	are	based	on	high	level	evidence,	28	on	moderate	evidence,	and	58	on	low	or	very	
low	evidence.	Two	interrelated	questions	arise	when	international	standards	are	based	on	such	
paltry	evidence.	First,	will	the	low	evidence,	and	accompanying	uncertainty,	lead	to	physician	
disagreement	and	poor	uptake	of	the	guidelines?	Second,	if	the	guidelines	are	applied,	will	they	
improve	outcomes	accepting	that	the	individual	elements	may	not	in	fact	work?	Together,	these	
issues	underpin	the	larger	question	of	whether	we	should	promote	and	use	guidelines	at	all.		
	
Increasing	standardization,	even	in	the	absence	of	known	efficacy,	has	the	advantage	of	promoting	
reliability.	This	may	facilitate	quicker	learning	about	good	versus	bad	processes,	simply	because	
random	noise	is	reduced	(Fig	2).	The	underlying	principle	of	seeking	to	reduce	variation	in	care	has	
some	rationale.	Quality	improvement	initiatives	based	on	SSC	bundles	have	been	associated	with	a	
reduction	in	sepsis	mortality	[6],	even	though	the	components	of	the	bundle	were	not	
demonstrated	to	lower	mortality	in	randomised	trials.	However,	compliance	is	rarely	high	for	any	
component	of	the	bundle	and	there	is	concern	that	forcing	uniform	management	based	on	weak	
evidence	may	inadvertently	cause	harm.	As	such,	one	should	be	careful	when	converting	
guidelines	into	mandates	[7].	
	
In	addition,	compliance	with	resuscitation	measures	in	the	3-	and	6-hour	SSC	bundles	is	highly	
variable	across	studies	[8-11],	suggesting	they	are	not	standards	of	care	across	all	settings	or	that	
the	guidelines	are	in	fact	difficult	to	follow	and	comply	with	even	in	excellent	centres.	A	
multinational	one-day	prevalence	study	also	showed	low	compliance	rates	with	all	resuscitation	
items,	including	lactate	sampling	(56%),	repeat	lactate	sampling	(64%),	administering	30	mL/kg	of	
crystalloids	for	fluid	resuscitation	(57%),	and	vasopressors	for	hypotension	(66%)	[10].	
	
Other	factors	that	decrease	compliance	with	resuscitation	guidelines	include	low	awareness	
among	healthcare	workers,	healthcare	workforce	shortages,	overcrowding	of	emergency	
departments	[11],	and	unfavourable	nurse-to-patient	ratios	[12].	Low	availability	of	resources	can	
also	limit	the	application	of	some	interventions.	For	example,	tools	to	assess	fluid	responsiveness	
may	be	unavailable	in	many	low	and	middle-income	settings.	Available	strategies	to	improve	
implementation	are	continuous	education	programs,	the	use	of	multidisciplinary	teams,	
reminders,	checklists,	and	mechanisms	of	audit	and	feedback	[13].		
The	best	standard	of	care	will	be	achieved	by	a	balance	between	the	best	available	evidence,	
identification	of	the	population	to	which	the	recommendation	may	not	apply	and	cause	harm,	and	
a	capacity	for	well-trained	and	experienced	physicians	to	weigh	the	balance	between	potential	
benefits	and	harms	for	a	specific	patient,	given	individual	circumstances	and	the	strength	of	the	
evidence.	
	
Major	recent	advances	in	septic	shock	
Positive	impact	of	negative	trials	
A	popular	critique	of	contemporary	trials	in	critical	care	has	been	that	these	trials	are	mostly	
‘negative’,	in	they	have	neither	brought	us	new	treatments	nor	shown	those	that	can	save	lives.	
However,	these	so-called	‘negative’	trials	have	nonetheless	generated	considerable	new	
knowledge	leading	both	to	scientific	advances	and	important	changes	in	clinical	practice	[14,	15].	
That	said,	individual	trials	continue	to	be	under-powered	to	detect	small	but	clinically	important	
effects	[16].	It	is	even	more	crucial	to	consider	the	comprehensive	body	of	evidence	to	answer	
research	questions.	For	example,	it	was	the	cumulative	contribution	of	31	trials,	conducted	
between	1982	and	2012,	that	established	the	harm	associated	with	hydroxyethyl	starch	(HES)	[17].	
	
Analyses	of	so-called	‘negative’	studies	have	informed	practice	in	three	ways.	First,	high-quality	
comparative	effectiveness	trials	that	do	not	report	a	statistically	significant	treatment	effect	in	
favour	of	the	intervention	can	provide	a	strong	rationale	to	guide	restriction	or	withdrawal	of	
ineffective	or	dangerous	interventions	(Fig.	2).	This	is	exemplified	by	the	HES	and	tight	glycaemic	
control	trials	that	showed	harm	from	the	interventions.	Second,	‘negative’	trials	may	identify	
important	subgroup	effects	that	support	more	individualized	care	to	a	heterogeneous	patient	
population	[18].	Third,	they	may	reveal	which	factors	are	important	in	multifaceted	interventions.	
The	results	of	the	original	Early	Goal-Directed	Therapy	(EGDT)	trial	[19]	were	not	reproduced	by	
three	concurrent	large	clinical	trials	[20–22].	The	pre-randomization	resuscitation	delivered	to	
patients	in	these	recent	trials	points	to	an	evolution	in	usual	care	and	suggests	that	clinician	
awareness	and	processes	of	care	(i.e.	prompt	recognition	and	reaction	to	acute	threats),	rather	
than	the	specific	aspects	of	resuscitation	protocols,	improve	outcomes.		
	
Large	international	collaborations	
The	need	for	adequate	statistical	power	to	demonstrate	clinically	relevant	reductions	in	effect	
sizes,	and	the	challenges	imposed	by	heterogeneous	patient	populations,	increase	the	already	
substantive	direct	and	indirect	costs	of	research.	The	establishment	of	successful	research	
collaborations	has	provided	exemplary	high-quality	trials.	The	emerging	trend	of	other	
international	research	collaborations,	particularly	in	middle-income	countries,	is	also	encouraging.	
From	the	perspective	of	research-funding	agencies,	these	collaborations	provide	an	efficient	
means	of	answering	important	clinical	questions	at	a	fraction	of	the	usual	cost.	Trials	of	EGDT-
directed	resuscitation	were	designed	to	facilitate	their	harmonization	in	an	individual	patient	data	
meta-analysis	[23,	24].	This	has	further	informed	best	practices	and	provided	the	power	to	explore	
important	subgroup	analyses.	Answering	the	important	questions	in	critical	care	research	will	
hinge	on	such	joint	international	efforts.	
	
Less	is	more	
A	constant	theme	from	research	reported	in	recent	years	has	been	that	less	is	often	more.	It	is	
justified	to	challenge	our	prior	beliefs	about	the	risk-benefit	balance	of	even	the	most	standard	
critical	care	interventions.	While	potentially	not	applicable	to	septic	shock	in	resource-rich	
environments,	the	increased	mortality	observed	with	fluid	boluses	in	African	children	with	severe	
febrile	illnesses	[25]	is	triggering	a	reassessment	of	the	safety	and	overall	effectiveness	of	
aggressive	fluid	resuscitation	beyond	surrogate	outcomes	such	as	urine	output	and	blood	
pressure.	New	data	from	Scandinavia	in	adults	with	septic	shock	support	these	observations	[26].	
More	aggressive	oxygen	therapy	may	also	be	associated	with	increased	mortality	[27].	These	
findings	require	confirmation,	but	are	consistent	with	the	experiences	and	subsequent	trials	in	
blood	transfusion,	glycaemic	control,	mechanical	ventilation	and	sedation	practices.	Our	patients	
are	highly	vulnerable	to	iatrogenic	complications;	there	is	an	equal	imperative	that	we	
systematically	seek	the	lowest	effective	dose	for	any	intervention.	
	
Patient/family	Involvement	
As	ICU	populations	are	becoming	older	and	frailer	[28]	reducing	short-term	mortality	may	not	
translate	into	significant	gains	in	quality-adjusted	life	years.	About	35%	of	patients	are	readmitted	
to	hospital	within	6	months	raising	to	60%	within	the	first	year	after	ICU	admission	for	sepsis	[29,	
30].	Cohort	studies	have	confirmed	that	specific	patient	populations,	particularly	older	patients	
who	receive	prolonged	ICU	care,	experience	an	increased	burden	of	chronic	physical	and	
psychological	disabilities	[31].	The	toll	of	long-term	ICU	care	sequelae	on	relatives	is	also	
increasingly	recognized	[32].	Despite	expert	recommendations	to	consider	non-mortal	outcomes	
in	certain	patient	populations,	most	septic	shock	research	continues	to	focus	on	short-term	
survival.	Determined	patient	stakeholders	have	requested	a	more	active	role	in	critical	care	
research	[33],	and	system-level	changes	are	taking	place	as	a	result	of	their	engagement	[34].	If	
septic	shock	research	embraces	these	initiatives,	increasing	emphasis	on	patient-centred	research	
may	prove	to	be	a	significant	advance	in	the	field.	
	
What	are	the	commonly	held	beliefs	that	have	been	contradicted	by	recent	trials	
in	septic	shock?	
For	the	management	of	septic	shock,	several	beliefs	have	been	contradicted	and	guideline	
recommendations	changed	or	challenged	following	the	publication	of	RCTs	and	systematic	reviews	
with	a	lower	risk	of	bias.	These	changes	represent	progress	within	the	field	that	should	prompt	
caution	among	clinicians,	guideline	committee	members	and	policy-makers,	especially	when	
assessing	results	of	trials	with	high-risk	of	bias	and	low	levels	of	external	validity.	
	
Early	goal-directed	therapy	(EGDT)	for	patients	with	septic	shock	
The	resuscitation	bundles	by	the	SSC	guidelines	were	based	on	the	concept	of	EGDT	produced	by	
the	results	of	a	small,	single-centred,	unblinded	trial	[19].	These	characteristics	may	have	
overestimated	the	effect	of	EGDT	[35–37].	This	prompted	the	conduct	of	three	RCTs	and	a	
systematic	review,	all	having	a	lower	risk	of	bias	and	greater	real-world	generalizability	[20–22,	24,	
38].		Together,	these	trials,	alone	and	in	combination,	demonstrated	no	effect	on	mortality	[24,	
38].	
	
Activated	protein	C	for	patients	with	septic	shock	and	high	risk	of	death	
The	use	of	APC	was	recommended	in	the	first	iteration	of	the	SSC	guidelines	following	the	
publication	of	an	RCT	(PROWESS)	reporting	reduced	mortality	in	patients	with	sepsis	with	the	use	
of	APC	[1].	A	subsequent	confirmatory	RCT	(PROWESS	Shock)	that	was	requested	by	Medical	
Regulatory	Authorities	[39],	reported	no	reduction	in	mortality	in	patients	with	septic	shock	[2],	
resulting	in	the	withdrawal	of	APC	from	the	market.	
	
Hydroxyethyl	starches	in	patients	with	septic	shock	
For	decades,	HES	solutions	were	used	in	the	fluid	management	of	patients	with	sepsis	based	on	
numerous	industry-driven	studies	including	some	that	was	subsequently	found	to	be	fraudulent.	
When	investigator-initiated	RCTs	with	low	risk	of	bias	were	conducted	marked	side-effects	and	
increased	mortality	were	observed	[40–42].	These	studies	have	resulted	in	substantive	changes	to	
medical	regulatory	authorisations	and	guidelines	that	either	prohibit	or	restrict	the	use	of	HES	[5,	
43].	
	
Blood	transfusion	in	patients	with	septic	shock	
The	SSC	guidelines	have	recommended	a	time-	and	biomarker-dependent	protocol	for	blood	
transfusion	based	on	the	results	of	the	initial	EGDT	trial	[19]	and	indirect	evidence	from	a	
multicentre	RCT	(TRICC)	in	ICU	patients	[44].	A	large	high-quality	confirmatory	RCT	showed	no	
differences	by	time-	and	biomarker-independent	blood	transfusion	at	haemoglobin	values	of	7	vs.	
9	g/dl	on	patient-centred	outcomes	in	patients	with	septic	shock	[45,	46].	
	
These	examples	support	the	meta-epidemiological	data	indicating	that	results	from	RCTs	with	
higher	vs.	lower	risk	of	bias	overestimate	intervention	effects	[35–37,	47,	48].	Similarly,	
observational	studies	are	likely	to	overestimate	intervention	effects	independent	of	the	method	of	
adjustment	[49].	These	effects	may	be	amplified	in	septic	shock	trials	where	multiple,	time-
dependent	exposures,	competing	risks	and	co-interventions	are	difficult	to	adjust	for	and	thus	will	
further	hamper	correct	interpretation.	The	imperative	for	clinician-researchers	is	to	test	as	many	
as	possible	of	the	interventions,	both	current	and	novel,	in	large,	multicentre	RCTs	with	the	lowest	
possible	risk	of	bias.	
	
What	are	remaining	areas	of	uncertainties?	
Look	at	those	SSC	Guideline	recommendations	based	on	low	quality	evidence	
The	SSC	Guidelines	[50]	use	the	GRADE	approach	to	generate	recommendations	for	clinical	care	
[51].	While	there	are	improvements	in	2016	iteration	of	the	guidelines	[5],	few	recommendations	
are	based	on	high-quality	evidence;	in	many	areas	uncertainty	remain.	
	
Antibiotics	
The	3-hour	and	6-hour	resuscitation	bundles	focused	on	antibiotic	therapy,	fluid	resuscitation	and	
blood	pressure	targets	(www.survivingsepsis.org/Bundles/Pages/default.aspx).	The	evidence	
pertaining	to	optimal	antibiotic	therapy	is	weak	despite	these	agents	being	the	cornerstone	of	
treating	infection,	the	trigger	for	sepsis	[4,	52].	There	is	little	equipoise	for	delayed	or	no	
antibiotics,	raising	practical	and	ethical	issues	over	any	efforts	to	generate	new	evidence	where	
patients	may	be	randomized	to	less	antibiotic	coverage.	Nevertheless,	the	evidence	base	that	
‘every	hour	counts’,	that	combination	therapy	is	beneficial,	and	that	long	courses	of	therapy	are	
needed	to	better	eradicate	microorganisms	is	weak	and	conflicting	(e.g.	[53,	54]).	Emerging	data	
suggest	harm	from	antibiotic	load,	be	it	from	longer	courses	and/or	multiple	agents.	Studies	of	
antimicrobial	therapies	seldom	report	mortality	differences	between	patients	treated	with	
appropriate	and	inappropriate	antibiotics,	and	also	differ	in	how	‘appropriate’	is	defined	[55].	Even	
if	the	microorganism	is	susceptible,	we	are	generally	unaware	if	the	patient	is	receiving	an	
adequate	dose	or	not.	Other	than	aminoglycosides	and	vancomycin,	antibiotic	dosing	is	seldom	
monitored.	There	is	therefore	great	uncertainty	whether	individual	patients	are	being	under-	or	
over-dosed	with	standard	regimens,	especially	as	drug	excretion,	metabolism,	volumes	of	
distribution,	protein	binding	and	augmented	renal	clearance	will	vary	markedly	in	sepsis	both	
temporally	within	patients	and	between	patients	[56,	57].	We	are	also	uncertain	whether	
monitoring	of	blood	levels	is	appropriate	to	ensure	adequate	concentrations	in	the	affected	area	
(e.g.	consolidated	lung	or	soiled	peritoneal	cavity),	and	whether	the	minimal	inhibitory	
concentration	(MIC)	measured	in	vitro	is	applicable	to	in	vivo	cure	or	failure	rates	[58].	In	the	
context	of	an	increasing	incidence	of	sepsis	[59,	60]	and	fast-emerging	antibiotic	resistance	[61],	
this	weak	evidence	base	is	disappointing	and	arguably	unacceptable.	We	must	rapidly	determine	
how	to	prescribe	antibiotics	optimally	for	both	efficacy	and	safety	[62].	
	Resuscitation	
The	‘6-hour	resuscitation	bundle’	–	based	upon	the	original	EGDT	[19]	targets	-	has	also	been	
shown	to	offer	no	advantage	over	standard	of	care	[24,	38].	Surely	we	must	re-evaluate	the	
benefit	of	recommending	rigid	physiological	targets	in	a	heterogeneous	population	where	one	size	
cannot	possibly	fit	all?	This	clearly	applies	to	the	volume	needed	to	achieve	‘adequate’	fluid	
resuscitation,	and	the	criteria	upon	which	‘adequate’	is	determined.	This	is	relevant	in	the	light	of	
a	recent	feasibility	trial	testing	a	more	restrictive	resuscitation	strategy	[26].	Similarly,	the	blood	
pressure	target	sufficient	to	achieve	an	adequate	but	not	excessive	organ	perfusion	pressure	is	
likely	to	vary	between	individuals.	Randomising	septic	shock	patients	to	two	fairly	fixed	blood	
pressure	targets	failed	to	demonstrate	overall	improvements	in	outcome		[63];	it	may	be	that	
better	pheno-	or	genotyping	could	stratify	patients	to	the	optimal	blood	pressure	target?	
	
New	definitions	and	trigger	tools	
The	new	sepsis	definitions	[4,	52]	have	explicitly	proposed	criteria	for	sepsis	and	septic	shock.	Re-
analyses	of	two	existing	trial	databases	have	provided	differing	results	regarding	the	potential	
interaction	of	the	new	definition	and	the	intervention	effect	[64,	65].	We	therefore	need	more	
such	analyses	to	better	estimate	the	potential	of	the	new	sepsis	definitions	to	change	the	
intervention	effect	estimates	observed	in	previous	trials.	In	addition,	the	new	criteria	include	a	
simple	physiology-based	score	(qSOFA)	to	identify	those	patients	with	suspected	infection	at	risk	
of	bad	outcomes	[66].	Several	track	and	trigger	tools	exist	and	differ	in	their	performance	and	
feasibility	of	implementation	[67].	Determining	the	best	tool	to	detect	the	at-risk	patient	with	
optimal	sensitivity	and	specificity	is	key.	
	
Mediator	modulation	
The	SSC	had	previously	abandoned	the	’24-hour	resuscitation	bundle’	[50]	as	three	(activated	
protein	C,	corticosteroids	for	shock,	tight	glycaemic	control)	of	the	4	components	were	shown	in	
subsequent	multicentre	trials	to	confer	no	benefit.	Similarly,	other	immunomodulatory	drugs	such	
as	intravenous	immunoglobulins	have	been	discarded	based	on	lack	of	overall	outcome	effect	
[68].	We	should	re-evaluate	such	treatment	‘failures’	by	using	predictive	or	prognostic	enrichment	
[69].	Treatment-responsive	sub-phenotypes	have	been	suggested	for	ARDS	[70]	and	sepsis	[71],	
and	these	need	to	be	explored	further.	We	need	to	identify	patients	in	whom	therapies	should	be	
avoided.	Immunosuppressive	agents	(such	as	steroids)	should	be	withheld	in	patients	found	to	be	
immunosuppressed,	whereas	immune-stimulatory	agents	(e.g.,	GM-CSF,	IFN-gamma,	or	PD-1	
inhibitors)	would	likely	further	aggravate	a	cytokine	storm	if	given	when	a	strong	pro-
inflammatory	phenotype	is	being	expressed	[72].		
	
Trial	design	
We	also	need	to	be	smarter	in	other	aspects	of	trial	design	(Fig.	3).	Many	studies	have	been	
unrealistically	powered	to	suit	funding	or	time	limitations;	type	II	error	is	thus	a	concern.	With	the	
advent	of	‘big	data’	[73],	we	should	be	able	to	better	characterise	patients	for	study	inclusion	and	
exclusion,	and	to	target	more	appropriate	study	endpoints	rather	than	mortality,	or	to	consider	
mortality	with	persisting	organ	failure	[74].	However,	choosing	composite	and/or	non-mortality	
endpoints	is	complex	[75];	improving	a	non-mortality	endpoint	may	not	necessarily	translate	into	
a	survival	benefit.	Adaptive	trial	design	can	also	increase	trial	efficiency	by	facilitating	earlier	
discard	of	ineffective	interventions	or	doses	of	drugs.	
	
What	are	the	top	10	topics	to	undergo	clinical	testing	in	septic	shock	in	the	next	10	
years?	
These	range	from	those	trials	ready	to	be	conducted	now	to	more	speculative	programs	for	later	
study	in	the	next	decade.	There	are	many	other	research	questions	to	be	answered,	in	particular	in	
less	resourced	settings,	but	it	is	beyond	the	scope	of	the	present	paper	to	cover	all	these.	
	
1.	Restrictive	vs.	liberal	fluid	resuscitation	
Although	fluid	therapy	is	a	fundamental	component	of	resuscitation	there	is	increasing	evidence	
that	excess	fluid	may	be	harmful	[25,	76].	However,	as	this	evidence	comes	from	retrospective	
studies	or	different	clinical	settings,	we	need	direct	evidence	from	RCTs	performed	in	the	different	
phases	of	septic	shock.	A	recent	pilot	trial	demonstrated	that	a	restrictive	vs.	liberal	fluid	strategy	
trial	is	feasible	after	initial	management	of	septic	shock	[26].	Similar	trials	of	the	fluid	management	
of	the	post-resuscitation	phase	of	septic	shock	are	needed	to	complement	existing	evidence	[77].	
	2.	Rapid	microbiology	diagnostic	and	antibiotic	measuring	devices	to	guide	therapy		
Early	appropriate	antibiotic	therapy	in	severely	ill	patients	is	critical	for	successful	sepsis	
management.	However,	in	less	severely	ill	patients	when	the	diagnosis	of	infection	is	less	clear	
there	is	evidence	that	waiting	for	positive	microbiology	results	may	be	appropriate	[78].	As	
antibiotic	resistance	rates	continue	to	rise,	avoiding	unnecessary	antibiotic	use	and	optimising	the	
dosing	of	those	used	are	high	priorities.	There	are	now	several	RCTs	evaluating	in	different	subsets	
of	potentially	infected	patients	whether	procalcitonin,	a	marker	of	host	response	to	infection,	
could	be	incorporated	into	antibiotic	prescribing	guidelines.	Novel	technology	now	allows	a	vast	
array	of	rapid	assays	of	both	microbial	products	and	host	response	to	infection	as	well	as	
assessment	of	antibiotic	pharmacokinetics	and	pharmacogenomics.	We	welcome	the	evaluation	of	
these	novel	diagnostics	in	trial	designs	similar	to	those	used	to	evaluate	procalcitonin	to	help	
guide	initiation,	selection,	dosing	and	duration	of	antibiotics.	
	
3.	Reducing	catecholamine	use	in	septic	shock	
The	potentially	favourable	effects	of	reduced	vasopressor	dosing	[79],	adjunctive	vasopressin	[80,	
81]	or	angiotensin-II	[82],	and/or	beta-blocker(s)	[83]	support	the	notion	that	excess	
catecholamines	be	limited	or	avoided	in	septic	shock.	There	is	an	imperative	to	conduct	trials	with	
low	risk	of	bias	to	assess	the	effectiveness	and	safety	of	strategies	aiming	at	reducing	the	effects	of	
catecholamines	in	septic	shock.	These	include	lowering	doses	of	noradrenaline	and	adjunctive	
vasopressin	analogues,	angiotensin-II	and/or	beta-blocking	agents.	For	these	strategies	to	be	
effective,	more	work	should	be	done	on	the	target	populations;	some	patients	may	be	harmed	by	
broad	application	of	these	interventions	to	unselected	populations.	Such	work	should	also	include	
pharmacogenomic	studies	as	there	are	functional	polymorphisms	of	both	alpha	and	beta	
adrenoreceptor	genes	that	affect	vascular	reactivity,	response	to	catecholamines,	and	risk	of	
sudden	death	[84,	85].	These	and	other	polymorphisms	in	vasopressor	pathway	genes	may	be	
associated	with	vasopressor	treatment	response,	serious	adverse	events	and	mortality	[86].	
	
4.	Counteracting	endocrine,	metabolic	and	bioenergetic	failure	
The	ADRENAL	trial	on	hydrocortisone	vs.	placebo	will	provide	important	information	about	the	use	
of	steroids	in	the	total	population	of	septic	shock	[87].	However,	trials	of	steroids	in	potentially	
treatment-responsive	subgroups	[88]	are	also	required.	Potential	interactions	with	vitamin	C	and	
thiamine	need	further	investigation	[89].	There	is	a	general	shift	in	energy	substrate	towards	fat	
metabolism	in	sepsis;	whether	this	is	beneficial	or	should	be	modulated	by,	for	instance,	ultra-
high-dose	insulin	or	ketones	warrants	study.	Mitochondrial	dysfunction	is	well	recognized	in	
human	sepsis	[90]	as	well	as	multiple	animal	models.	Bioenergetic	failure	is	increasingly	
recognized	as	an	important	aetiology	of	immune	dysfunction.	Protecting	mitochondria	(e.g.	with	
targeted	antioxidants	[91])	or	stimulating	mitochondrial	biogenesis	[92]	with	regeneration	of	new,	
functioning	mitochondria	are	strategies	that	may	prove	efficacious.		
	
5.	Stem	cell	therapies	
Past	attempts	to	modulate	the	immune	response	have	been	unsuccessful,	perhaps	because	of	the	
multiple	redundant	pathways	in	multiple	cell	types	that	are	activated	in	any	individual	septic	
patient.	Mesenchymal	stromal	stem	cells	target	multiple	pathways,	interact	with	multiple	cell	
types,	and	may	be	appropriately	responsive	to	the	inflammatory	environment.	Experimental	and	
early	clinical	studies	show	promising	results	and	now	need	to	be	tested	in	larger	RCTs	[93].	
	
6.	Biomarker-guided	trials	
Attempts	to	inhibit	the	systemic	inflammatory	response	in	sepsis	have	failed	to	reduce	mortality	
and,	in	some	cases,	increased	mortality	[94].	Although	the	inflammatory	response	has	important	
protective	effects,	an	anti-inflammatory	intervention	likely	only	works	if	there	is	excessive	
inflammation.	Initial	attempts	to	target	the	most	severely	inflamed	patients	using	a	general	
marker	of	inflammation	failed	to	improve	outcomes	[95].	Future	RCTs	that	use	specific	predictive	
biomarkers	[88]	and	pharmacogenomic	biomarkers	of	response	to	drug(s)	that	are	the	target	for	
the	intervention,	should	be	used	to	select	patients	for	inclusion	in	many	future	trials.	
	
7.	Novel	anti-inflammatory	therapies	
As	detailed	above,	therapies	targeting	the	host	inflammatory	response	to	sepsis	have	failed.	An	
interesting	alternative	is	to	target	the	organism	to	reduce	inflammation.	Proprotein	convertase	
subtilisin/kexin	type-9	(PCSK9)	inhibitors	lower	low	density	lipoprotein	(LDL)	levels	and	may	also	
increase	clearance	of	pathogen	lipids,	such	as	LPS,	transported	in	LDL	[96].	This	novel	therapeutic	
strategy	requires	further	basic	and	clinical	trial	investigations.	As	genetic	PCSK9	variants	affect	
PCSK9	function,	a	predictive	pharmacogenetic	strategy	should	be	investigated	in	these	trials.	
	
8.	Biomarker-guided	immune	stimulation	trial	
There	is	also	an	important	anti-inflammatory	host	response	in	sepsis	that	may	lead	to	secondary	
infection	and	poor	outcomes.	A	recent	study	in	patients	with	community-acquired	pneumonia	
examining	gene-expression	profiles	identified	a	subgroup	of	patients	who	had	an	immune-
suppressed	phenotype	and	higher	mortality	rate	than	patients	without	the	immuno-suppression	
[97].	Such	immunosuppressed	patients	may	benefit	from	treatment	with	immunostimulant	
therapies	such	as	IL-7	(NCT02640807),	anti-PDL1	and	other	immuno-stimulating	interventions	[98].	
		
9.	The	use	of	machine	learning	algorithms	/	computer	decision	support	systems	
Growing	use	of	electronic	health	records	creates	huge	databases	containing	valuable	information	
about	demographics,	altered	pathophysiology	and	response	to	various	treatments	of	sepsis.	
Machine	learning	techniques	embedded	in	clinical	decision	support	systems	should	be	developed	
and	tested	to	select	“optimal”	treatments	in	sepsis	using	data-driven	models	[99].	These	offer	the	
tantalising	prospect	of	better	precision-based	decision	making	for	the	individual	patient	
(characteristics	and	disease	trajectories)	to	improve	outcome.		
	
10.	Multi-arm,	multi-stage	trials	of	common	sepsis	therapies	–	“all	in”	
This	review	has	highlighted	several	proposed	trials	of	individual	treatments	in	sepsis.	Undoubtedly,	
there	are	other	new	therapies	being	developed.	Furthermore,	septic	patients	require	multiple	
treatments	in	combination	and	these	interactions	also	require	testing.	Running	separate	RCTs	for	
each	therapy	and	each	combination	is	a	massive	investment.	The	advent	of	long-term	platform	
trials	with	multiple	treatment	arms	and	multiple	stages,	in	which	treatments	may	be	dropped	or	
added	(optimally	by	using	adaptive	trial	design),	has	provided	multi-component	successes	within	
oncology	[100].	Long-term	platform	trials	should	now	be	set-up	for	sepsis	[101]	(Fig.	2).	
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Figure	legend	
	
Fig.	1.	Sources	of	heterogeneity	among	patients	with	sepsis	
	
Fig.	2.	The	contribution	of	trial	results	(positive,	negative	or	neutral)	to	the	continued	evolvement	
of	clinical	practice	and	new	research	questions	to	be	tested	in	new	trials	(darker	blue	circles).	In	
this	process,	explorative	analyses	of	trial	results,	the	harmonization	of	care	and	increased	
utilisation	of	enrichment	through	improved	geno-	and	phenotyping	and	novel	trial	designs	(lighter	
blue)	will	all	contribute	to	the	conduct	of	better,	more	effective	and	more	efficient	trials.	
	
Fig.	3.	Enrichment	and	Biomarker	Stratified	designs.	Enrichment	designs	could	be	either	predictive	
enrichment	or	prognostic	enrichment	or	combination	of	both	[102].	Predictive	enrichment	refers	
to	enriching	patients	based	on	greater	likelihood	of	treatment	response	irrespective	of	illness	
severity	(Fig	3a).	Prognostic	enrichment	identifies	a	patient	population	at	high	risk	of	outcome	
event	and	randomise	them	for	interventions	(Fig.	3b).	Treatment	response	marker(s)	negative	
population	in	predictive	enrichment	design,	and	the	low	risk	of	outcome	population	in	prognostic	
enrichment	design,	are	excluded	from	the	trial.	If	a	significant	average	treatment	effect	is	
observed,	it	recommended	only	for	the	tested	population.	Treatment	response	marker(s)	
stratified	design	randomises	both	positive	and	negative	population	(Fig	3c).	Analyses	are	
conducted	in	two	stages.	First,	the	treatment	response	marker(s)	positive	population	is	tested	for	
difference	in	outcomes.	If	there	is	a	difference	in	average	treatment	effect	in	the	treatment	
response	marker(s)	positive	population,	then	a	second	set	of	analyses	are	conducted.	This	could	
be	done	either	in	the	treatment	response	marker(s)	negative	population	or	to	the	whole	
population	to	generate	treatment	recommendations.	
	
	
